Standard

Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1 : A Transcriptome Profiling Study. / Stefanova, Natalia A.; Ershov, Nikita I.; Kolosova, Nataliya G.

In: Oxidative medicine and cellular longevity, Vol. 2019, 3984906, 15.07.2019.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Stefanova, N. A., Ershov, N. I., & Kolosova, N. G. (2019). Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study. Oxidative medicine and cellular longevity, 2019, [3984906]. https://doi.org/10.1155/2019/3984906

Vancouver

Stefanova NA, Ershov NI, Kolosova NG. Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study. Oxidative medicine and cellular longevity. 2019 Jul 15;2019:3984906. doi: 10.1155/2019/3984906

Author

Stefanova, Natalia A. ; Ershov, Nikita I. ; Kolosova, Nataliya G. / Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1 : A Transcriptome Profiling Study. In: Oxidative medicine and cellular longevity. 2019 ; Vol. 2019.

BibTeX

@article{8e3a09106ec44fb38e54c18d137f55d7,
title = "Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study",
abstract = "Alzheimer's disease (AD) is the most common type of dementia, with increasing prevalence and no disease-modifying treatment available yet. There is increasing evidence-from interventions targeting mitochondria-that may shed some light on new strategies for the treatment of AD. Previously, using senescence-accelerated OXYS rats that simulate key characteristics of sporadic AD, we have shown that treatment with mitochondria-targeted antioxidant SkQ1 (plastoquinonyl-decyltriphenylphosphonium) from age 12 to 18 months (that is, during active progression of AD-like pathology)-via improvement of mitochondrial function-prevented the neuronal loss and synaptic damage, enhanced neurotrophic supply, and decreased amyloid-β1-42 protein levels and tau hyperphosphorylation in the hippocampus. In the present study, we continued to explore the mechanisms of the anti-AD effects of SkQ1 in an OXYS rat model through deep RNA sequencing (RNA-seq) and focused upon the cell-specific gene expression alterations in the hippocampus. According to RNA-seq results, OXYS rats had 1,159 differentially expressed genes (DEGs) relative to Wistar rats (control), and 6-month treatment with SkQ1 decreased their number twofold. We found that 10.5% of all DEGs in untreated (control) OXYS rats were associated with mitochondrial function, whereas SkQ1 eliminated differences in the expression of 76% of DEGs (93 from 122 genes). Using transcriptome approaches, we found that the anti-AD effects of SkQ1 are associated with an improvement of the activity of many signaling pathways and intracellular processes. SkQ1 changed the expression of genes in neuronal, glial, and endothelial cells, and these genes are related to mitochondrial function, neurotrophic and synaptic activity, calcium processes, immune and cerebrovascular systems, catabolism, degradation, and apoptosis. Thus, RNA-seq analysis yields a detailed picture of transcriptional changes during the development of AD-like pathology and can point to the molecular and genetic mechanisms of action of the agents (including SkQ1) holding promise for the prevention and treatment of AD.",
keywords = "ACCELERATED OXYS RATS, OXIDATIVE STRESS, SENESCENCE, BRAIN, MICROGLIA, SUPPLEMENTATION, ACCUMULATION, HIPPOCAMPUS, HOMEOSTASIS, EXPRESSION",
author = "Stefanova, {Natalia A.} and Ershov, {Nikita I.} and Kolosova, {Nataliya G.}",
note = "Publisher Copyright: {\textcopyright} 2019 Natalia A. Stefanova et al. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2019",
month = jul,
day = "15",
doi = "10.1155/2019/3984906",
language = "English",
volume = "2019",
journal = "Oxidative medicine and cellular longevity",
issn = "1942-0900",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1

T2 - A Transcriptome Profiling Study

AU - Stefanova, Natalia A.

AU - Ershov, Nikita I.

AU - Kolosova, Nataliya G.

N1 - Publisher Copyright: © 2019 Natalia A. Stefanova et al. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2019/7/15

Y1 - 2019/7/15

N2 - Alzheimer's disease (AD) is the most common type of dementia, with increasing prevalence and no disease-modifying treatment available yet. There is increasing evidence-from interventions targeting mitochondria-that may shed some light on new strategies for the treatment of AD. Previously, using senescence-accelerated OXYS rats that simulate key characteristics of sporadic AD, we have shown that treatment with mitochondria-targeted antioxidant SkQ1 (plastoquinonyl-decyltriphenylphosphonium) from age 12 to 18 months (that is, during active progression of AD-like pathology)-via improvement of mitochondrial function-prevented the neuronal loss and synaptic damage, enhanced neurotrophic supply, and decreased amyloid-β1-42 protein levels and tau hyperphosphorylation in the hippocampus. In the present study, we continued to explore the mechanisms of the anti-AD effects of SkQ1 in an OXYS rat model through deep RNA sequencing (RNA-seq) and focused upon the cell-specific gene expression alterations in the hippocampus. According to RNA-seq results, OXYS rats had 1,159 differentially expressed genes (DEGs) relative to Wistar rats (control), and 6-month treatment with SkQ1 decreased their number twofold. We found that 10.5% of all DEGs in untreated (control) OXYS rats were associated with mitochondrial function, whereas SkQ1 eliminated differences in the expression of 76% of DEGs (93 from 122 genes). Using transcriptome approaches, we found that the anti-AD effects of SkQ1 are associated with an improvement of the activity of many signaling pathways and intracellular processes. SkQ1 changed the expression of genes in neuronal, glial, and endothelial cells, and these genes are related to mitochondrial function, neurotrophic and synaptic activity, calcium processes, immune and cerebrovascular systems, catabolism, degradation, and apoptosis. Thus, RNA-seq analysis yields a detailed picture of transcriptional changes during the development of AD-like pathology and can point to the molecular and genetic mechanisms of action of the agents (including SkQ1) holding promise for the prevention and treatment of AD.

AB - Alzheimer's disease (AD) is the most common type of dementia, with increasing prevalence and no disease-modifying treatment available yet. There is increasing evidence-from interventions targeting mitochondria-that may shed some light on new strategies for the treatment of AD. Previously, using senescence-accelerated OXYS rats that simulate key characteristics of sporadic AD, we have shown that treatment with mitochondria-targeted antioxidant SkQ1 (plastoquinonyl-decyltriphenylphosphonium) from age 12 to 18 months (that is, during active progression of AD-like pathology)-via improvement of mitochondrial function-prevented the neuronal loss and synaptic damage, enhanced neurotrophic supply, and decreased amyloid-β1-42 protein levels and tau hyperphosphorylation in the hippocampus. In the present study, we continued to explore the mechanisms of the anti-AD effects of SkQ1 in an OXYS rat model through deep RNA sequencing (RNA-seq) and focused upon the cell-specific gene expression alterations in the hippocampus. According to RNA-seq results, OXYS rats had 1,159 differentially expressed genes (DEGs) relative to Wistar rats (control), and 6-month treatment with SkQ1 decreased their number twofold. We found that 10.5% of all DEGs in untreated (control) OXYS rats were associated with mitochondrial function, whereas SkQ1 eliminated differences in the expression of 76% of DEGs (93 from 122 genes). Using transcriptome approaches, we found that the anti-AD effects of SkQ1 are associated with an improvement of the activity of many signaling pathways and intracellular processes. SkQ1 changed the expression of genes in neuronal, glial, and endothelial cells, and these genes are related to mitochondrial function, neurotrophic and synaptic activity, calcium processes, immune and cerebrovascular systems, catabolism, degradation, and apoptosis. Thus, RNA-seq analysis yields a detailed picture of transcriptional changes during the development of AD-like pathology and can point to the molecular and genetic mechanisms of action of the agents (including SkQ1) holding promise for the prevention and treatment of AD.

KW - ACCELERATED OXYS RATS

KW - OXIDATIVE STRESS

KW - SENESCENCE

KW - BRAIN

KW - MICROGLIA

KW - SUPPLEMENTATION

KW - ACCUMULATION

KW - HIPPOCAMPUS

KW - HOMEOSTASIS

KW - EXPRESSION

UR - http://www.scopus.com/inward/record.url?scp=85071280184&partnerID=8YFLogxK

U2 - 10.1155/2019/3984906

DO - 10.1155/2019/3984906

M3 - Article

C2 - 31396299

VL - 2019

JO - Oxidative medicine and cellular longevity

JF - Oxidative medicine and cellular longevity

SN - 1942-0900

M1 - 3984906

ER -

ID: 21345973